Recent Advancements of Molecular Biomarkers in Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 116
Special Issue Editor
Interests: breast cancer; urogenital cancers; neuropathology; molecular pathology; digital pathology; tumor microenvironment
Special Issue Information
Dear Colleagues,
This Special Issue focuses on recent advancements in molecular biomarkers in cancer. Cancer is a complex disease, and biomarkers are crucial tools for its diagnosis, prognosis, and monitoring. This Special Issue aims to provide a comprehensive overview of the latest breakthroughs in this field, concentrating on molecular biomarkers that hold significant potential for improving cancer detection, treatment, and patient outcomes.
The scope of this Special Issue encompasses various aspects of molecular biomarkers in cancer research. It includes advancements in identifying and characterizing novel cancer-specific biomarkers, elucidating their role in tumorigenesis, and assessing their clinical utility. Importantly, this Special Issue will delve into cutting-edge technologies and techniques used for biomarker discovery and validation. This will encompass next-generation sequencing, proteomics, metabolomics, and other high-throughput approaches that enable the identification of promising biomarker candidates.
Moreover, this Special Issue will also explore the role of molecular biomarkers in personalized medicine and precision oncology. It will shed light on how these biomarkers can guide treatment decisions, predict therapy response, and improve patient stratification. Additionally, this Special Issue will include discussions on the challenges associated with translating biomarker discoveries into actionable clinical applications, emphasizing the need for robust validation studies and harmonized regulatory frameworks.
Overall, this Special Issue serves as a platform for researchers and clinicians to access the latest advancements in molecular biomarkers in cancer, driving the development of more effective and tailored approaches for cancer management.
Dr. Giuseppe Nicolò Fanelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular biomarkers
- cancer research
- precision medicine
- tumor profiling
- genomic signatures
- personalized oncology
- biomarker discovery
